Analysis of Expression of Specific Markers in Hepatocellular Carcinoma

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Hepatocellular Carcinoma

Treatments: Other: Retrospective analysis of already archived samples

Study type: Observational

Funder types: Industry

Identifiers

NCT00858000

111722

Details and patient eligibility

About

Hepatocellular carcinoma is an aggressive disease with limited therapeutic options. Therefore, new approaches to treat this type of cancer are needed with immunotherapy potentially being one of these. As a first step in the development of novel therapies, expression analysis of specific markers, including tumor antigens will be carried out. This will be done retrospectively using available hepatocellular carcinoma tissue samples.

Enrollment: 30 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• The patient had pathologically proven hepatocellular carcinoma
• All the data required are available from patient's records
• A sufficient amount of RNA is available for all three tissue samples

Exclusion criteria

N/A

Trial design

30 participants in 1 patient group

Group A

Description:

No intervention

Treatment:

Other: Retrospective analysis of already archived samples